662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma - Rohit Jain; Yuanquan Yang; Amir Mortazavi; Jingsong Zhang; Jasreman Dhillon; Youngchul Kim; Wenyi Fan; Guru P Sonpavde; Juskaran Chadha; Monica Chatwal; Sarah Raymond; Erika Saunders; et al. (Journal for ImmunoTherapy of Cancer, 2023)